| Name | Title | Contact Details |
|---|---|---|
Bruno Galea |
Head of R&D IT Healthcare Operations | Profile |
John Lee |
Associate Director, Financial Planning & Analysis, Biopharma R&D | Profile |
Cécile Lloret Jefford |
Director, R&D Strategy Implementation Leader - Strategic Business Development Operations | Profile |
Jennifer Tose |
Sector HR Business Partner (Director), Healthcare R&D | Profile |
Rafaela Endert |
Development Chief of Staff - Healthcare R&D | Profile |
BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.
Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.
Cell Therapeutics, Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.